Combining NMR and molecular modelling in a drug delivery context: investigation of the multi-mode inclusion of a new NPY-5 antagonist bromobenzenesulfonamide into beta-cyclodextrin.
Gloria Uccello-Barretta, Federica Balzano, Giuseppe Sicoli, Carmen Fríglola, Ignacio Aldana, Antonio Monge, Donatella Paolino, Salvatore Guccione
Index: Bioorg. Med. Chem. 12(2) , 447-58, (2004)
Full Text: HTML
Abstract
NMR spectroscopic and molecular modelling methods have been employed to describe the complexation of trans-N-4-[N'-(4-chlorobenzoyl)hydrazinocarbonyl]cyclohexylmethyl-4-bromobenzenesulfonamide, a new chemotype of NPY-5 antagonist, and beta-cyclodextrin, revealing the coexistence of two different kinds of 1:1 complexes where conformational changes of the guest compound with respect to the free state are also detected.
Related Compounds
Related Articles:
2006-08-01
[Bioorg. Med. Chem. 14(15) , 5259-65, (2006)]
Metabolites of ebrotidine, a new H2-receptor antagonist, in human urine.
1994-02-01
[J. Pharm. Sci. 83(2) , 252-4, (1994)]
2001-01-01
[Electrophoresis 22(1) , 71-6, (2001)]
Preparation of novel cobalt (III) complexes with dithiocarbimates derived from sulfonamides. Oliveira MRL and Bellis VMD.
[Transit. Met. Chem. 24(2) , 127-130, (1999)]